Optimizing Kevzara Prior Authorization for Gastroenterology Workflows

Navigating Kevzara prior authorization for gastroenterology patients requires precise documentation and adherence to evolving payer policies. Klivira streamlines this complex process, ensuring efficient approval for essential therapies.

While Kevzara (sarilumab) is primarily indicated for rheumatologic conditions, any biologic prior authorization (PA) presents significant administrative challenges for gastroenterology practices. Managing high-volume PA categories like IBD biologics, Hep C DAAs, and complex procedures already strains revenue cycle teams. Klivira integrates directly with EMRs to automate the critical steps, from documentation gathering to submission, for all biologic therapies.

Kevzara Prior Authorization: General Considerations for Biologics

Kevzara (sarilumab), an IL-6 receptor blocker, is a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans. While its primary indications are outside core gastroenterology, the administrative burden associated with securing PA for biologics is universal. GI practices frequently manage patients with complex comorbidities where biologics are prescribed, necessitating robust PA processes.

Essential Documentation for Biologic Prior Authorizations in Gastroenterology

Diagnosis confirmation and disease severity assessment (e.g., Mayo score for UC, CDAI for Crohn's, or other relevant disease activity indices).
Documentation of prior conventional therapy trials and step therapy compliance.
Results of pre-initiation screenings (e.g., TB, hepatitis) as per ACG/AGA guidelines.
Payer-specific medical necessity criteria for the prescribed biologic agent.
Patient's treatment history, including previous biologic experience.

Mitigating Common Prior Authorization Denials for Biologics in GI

Non-compliance with payer-mandated step therapy protocols.
Insufficient documentation of disease severity or prior treatment failures.
Missing or incomplete pre-initiation screening results (e.g., TB, hepatitis).
Failure to adhere to biosimilar substitution requirements where applicable.
Treatment-naive vs. treatment-experienced misclassification affecting pathway.

Klivira's Automated Solution for Gastroenterology Biologic PAs

Klivira's platform is engineered to address the specific prior authorization challenges faced by gastroenterology practices, including those for high-volume biologics. Our system leverages ACG/AGA-guideline-aware logic for complex step therapy sequencing and automates the extraction of critical documentation from your EMR, such as diagnosis codes, lab results, and medication histories. This ensures submissions meet payer-specific requirements, reducing manual effort and accelerating approval times.

Addressing Chronic Treatment and Re-authorization Cycles

Gastroenterology often involves chronic biologic therapies requiring periodic re-authorization, a significant ongoing PA burden. Klivira's system tracks re-authorization cadences and proactively initiates the process, prompting for updated disease response documentation. This continuous monitoring minimizes treatment disruptions and ensures compliance with evolving payer policies for ongoing biologic regimens.

Seamless EMR Integration and Payer Connectivity

Klivira integrates with leading EMR systems via SMART on FHIR, enabling secure and efficient data exchange. This connectivity facilitates automated documentation retrieval, populating X12 278 transactions or payer portal fields with precision. Our platform connects to a broad network of payer portals, ensuring submissions are routed correctly and tracked in real-time, regardless of whether the biologic falls under medical or pharmacy benefit.

Frequently asked questions

How does Klivira handle the distinction between medical and pharmacy benefit for biologics?

Klivira's platform is designed to identify and route biologic prior authorizations correctly, whether they fall under the medical or pharmacy benefit. Our system accommodates the nuances of administration mode changes, ensuring the appropriate documentation and submission channels are utilized, minimizing delays due to benefit misclassification.

Can Klivira adapt to payer-specific step therapy requirements for biologics?

Yes, Klivira incorporates comprehensive payer-policy logic that is continually updated. For biologics, this includes ACG/AGA-guideline-aware step therapy rules, biosimilar mandates, and treatment-naive versus experienced pathways. Our system guides users through these requirements, ensuring submissions are compliant with each payer's specific criteria.

What EMR systems does Klivira integrate with for GI prior authorizations?

Klivira offers robust integration capabilities with major EMR systems using SMART on FHIR standards. This allows for seamless extraction of patient data, medication histories, and diagnostic results critical for GI prior authorizations, including those for biologics, procedures, and advanced imaging.

How does Klivira help reduce denials for biologic therapies in gastroenterology?

Klivira reduces denials by ensuring complete and accurate documentation, adherence to payer-specific medical necessity criteria, and correct step therapy sequencing. Our system flags potential issues before submission, such as missing pre-screening results or insufficient disease severity scores, proactively preventing common denial reasons.